Search - tctmd.com

Displaying 1 - 20 of 763

Sort: Relevancy | Date

News Daily News

STAR Trial Gives Insight Into Two-Stage CTO PCI in Complex Patients

Yael L. Maxwell

December 05, 2025

News Conference News TCT 2025

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Yael L. Maxwell

November 07, 2025

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

Presentation TCT 2025

TCT 467: Comparative Long-Term Outcomes Of Sirolimus vs Paclitaxel-Coated Balloons In STEMI: A Retrospective Analysis

Presenter: Bhagya Harindi Loku Waduge

October 27, 2025

Presentation TCT 2025

TCT 468: Comparison of Limus and Paclitaxel Drug-Coated Balloons, 2nd-generation or Newer Drug-Eluting Stents, and Balloon Angioplasty: A Network Meta-Analysis of Randomized Controlled Trials

Presenter: Yuko Kiyohara

October 27, 2025

Presentation TCT 2025

TCT 469: Comparative Outcomes of Sirolimus versus Paclitaxel-Coated Balloon Angioplasty in De Novo Coronary Lesions: Real-World Data

Presenter: Bhagya Harindi Loku Waduge

October 27, 2025

Presentation TCT 2025

TCT 515: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Diabetes Mellitus

Presenter: David Erlinge

October 27, 2025

Presentation TCT 2025

TCT 510: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Long Coronary Artery Lesions

Presenter: David Erlinge

October 27, 2025

Presentation TCT 2025

TCT 511: Paclitaxel-Coated Balloons versus Newer-Generation Drug-Eluting Stents for De Novo Coronary Artery Lesions: A Meta-Analysis of Randomized Controlled Trials

Presenter: Kamil Bujak

October 27, 2025

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

Presentation TCT 2025

Two-year Outcome of Sirolimus-coated Versus Paclitaxel-coated Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: Evidence from the Randomized SIRONA Trial

Presenter: Ulf Teichgräber

October 26, 2025

Presentation TCT 2025

TCT 464: Comparative Effectiveness and Safety of Low-Dose versus High-Dose Paclitaxel Drug-Coated Balloons for Femoropopliteal Artery Disease: One-Year Results from the DCB-SFA Randomized Trial

Presenter: Seung-Whan Lee

October 26, 2025

Presentation TCT 2025

TCT 178: Use of the AGENT Paclitaxel-Coated Balloon in the United States Shortly After FDA Approval: Early Results from the AGENT Post-Approval Study

Presenter: Christina Lalani

October 26, 2025

Presentation TCT 2025

TCT 180: Paclitaxel-Coated Balloon versus Uncoated Balloon for Coronary In-Stent Restenosis in Patients with Acute Coronary Syndromes: A Subanalysis of the AGENT IDE Trial

Presenter: Neal S. Kleiman

October 26, 2025

Presentation TCT 2025

TCT 182: Impact of Lesion Preparation Strategy on the Efficacy of Paclitaxel Coated Balloon for Coronary In-stent Restenosis: A Subgroup Analysis of the AGENT IDE Randomized Trial

Presenter: Aditya Mantha

October 26, 2025

Presentation TCT 2025

TCT 181: Efficacy and Safety of Coronary Angioplasty Using a Paclitaxel-Coated vs Uncoated Balloon in Patients with In-Stent Restenosis Stratified by Restenosis Risk: A Subanalysis of the AGENT IDE

Presenter: Prakriti Gaba

October 26, 2025

Presentation TCT 2025

Real-World Registry of Paclitaxel Drug-Coated Balloon for Native Coronary Artery Disease Treatment

Presenter: Masato Nakamura

October 25, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2025

Michael O'Riordan

September 30, 2025

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

L.A. McKeown

September 05, 2025

Advertisement

STAR Trial Gives Insight Into Two-Stage CTO PCI in Complex Patients

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

TCT 467: Comparative Long-Term Outcomes Of Sirolimus vs Paclitaxel-Coated Balloons In STEMI: A Retrospective Analysis

TCT 468: Comparison of Limus and Paclitaxel Drug-Coated Balloons, 2nd-generation or Newer Drug-Eluting Stents, and Balloon Angioplasty: A Network Meta-Analysis of Randomized Controlled Trials

TCT 469: Comparative Outcomes of Sirolimus versus Paclitaxel-Coated Balloon Angioplasty in De Novo Coronary Lesions: Real-World Data

TCT 515: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Diabetes Mellitus

TCT 510: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Long Coronary Artery Lesions

TCT 511: Paclitaxel-Coated Balloons versus Newer-Generation Drug-Eluting Stents for De Novo Coronary Artery Lesions: A Meta-Analysis of Randomized Controlled Trials

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Two-year Outcome of Sirolimus-coated Versus Paclitaxel-coated Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: Evidence from the Randomized SIRONA Trial

TCT 464: Comparative Effectiveness and Safety of Low-Dose versus High-Dose Paclitaxel Drug-Coated Balloons for Femoropopliteal Artery Disease: One-Year Results from the DCB-SFA Randomized Trial

TCT 178: Use of the AGENT Paclitaxel-Coated Balloon in the United States Shortly After FDA Approval: Early Results from the AGENT Post-Approval Study

TCT 180: Paclitaxel-Coated Balloon versus Uncoated Balloon for Coronary In-Stent Restenosis in Patients with Acute Coronary Syndromes: A Subanalysis of the AGENT IDE Trial

TCT 182: Impact of Lesion Preparation Strategy on the Efficacy of Paclitaxel Coated Balloon for Coronary In-stent Restenosis: A Subgroup Analysis of the AGENT IDE Randomized Trial

TCT 181: Efficacy and Safety of Coronary Angioplasty Using a Paclitaxel-Coated vs Uncoated Balloon in Patients with In-Stent Restenosis Stratified by Restenosis Risk: A Subanalysis of the AGENT IDE

Real-World Registry of Paclitaxel Drug-Coated Balloon for Native Coronary Artery Disease Treatment

What’s Going to Be Hot at TCT 2025

TCTMD’s Top 10 Most Popular Stories for September 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content